Data Published in New England Journal of Medicine Shows Pfizer's Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia
Trial demonstrates cumulative incidence of death or respiratory failure through day 28 was 18.1% with tofacitinib compared to 29.0% with placebo, in hospitalized patients with COVID-19 pneumonia Multi-center, randomized, double-blind, placebo-controlled trial conducted across 15 sites in Brazil Tofacitinib is not approved or authorized for the treatment of COVID-19 patients. Tofacitinib should not be used in … Trial demonstrates cumulative incidence of death or respiratory failure through day 28 was 18.1% (26 of 144) with tofacitinib compared to 29.0% (42 of 145) with placebo, in hospitali...